Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Polaryx Therapeutics Inc (PLYX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.80+4.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PLYX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successfully raise capital without excessive dilution | A supporting condition in Polaryx Therapeutics Inc's published investment case. The stated target is raise sufficient capital to fund operations for next 12 months. | Intact | failure to raise capital or excessive dilution beyond recent levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, clinical-stage biotech story, not an established earnings compounder. The thesis is intact, but confidence is low and risk is elevated because the business is loss-making and recent financial performance is neutral.
The evidence does not include a valuation comparison or a clear account of market expectations, so whether the shares are cheap, fair, or expensive versus peers cannot be assessed. The available evidence points to expectations centered on advancing PLX-200 and launching the SOTERIA Phase 2 trial, rather than demonstrated profits.
Near term, the company has funding from a $10 million private placement, which is expected to extend its operating runway through 2027-Q2; the SOTERIA trial is planned to begin in Q4 2026. PLX-200 has FDA Fast Track designation for four rare disease indications, but clinical progress is still the key execution test. Near-term risk remains elevated, and the evidence flags the next company update as worth watching.
The multi-year thesis hinges on the SOTERIA trial starting on schedule and on meaningful progress in PLX-200 clinical development. Broader conditions also matter: weaker jobs data could increase recession concerns, while results and guidance from healthcare bellwethers could strengthen or weaken the sector backdrop.
Over the next 1 to 3 years, PLYX remains an early-stage clinical development story with a funded runway and an important trial milestone ahead, but with limited evidence of financial strength and elevated execution risk. The thesis is intact, though confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Polaryx is focused on managing its operating losses near $2 million per quarter. |
| Broken |
| cash flow from operations worsens beyond negative $2 million per quarter |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating losses near negative $2 million per quarter | Polaryx is focused on managing its operating losses near $2 million per quarter. | Broken | operating loss worsens beyond negative $2 million per quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.28 → $-0.29 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-25 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-26 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-28 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-29 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-30 | $-0.28 | Unavailable | 1 / 0 |
| 2026-07-31 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-01 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-02 | $-0.27 | $0 | 3 / 3 |
| 2026-08-03 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-04 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-05 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-06 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-07 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-08 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-09 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-10 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-12 | $-0.27 | $0 | 3 / 3 |
| 2026-08-13 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-14 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-15 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-16 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-17 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-18 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-19 | $-0.27 | Unavailable | 2 / 0 |
| 2026-08-20 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-21 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-22 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-23 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-24 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-25 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-26 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-27 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-28 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-29 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-30 | $-0.29 | Unavailable | 3 / 0 |
| 2026-08-31 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-01 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-02 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-03 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-04 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-05 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-06 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-07 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-08 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-09 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-10 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-11 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-12 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-13 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-14 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-15 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-16 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-17 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-18 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-19 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-20 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-21 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-22 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-23 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-24 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-25 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-26 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-27 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-28 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-29 | $-0.29 | Unavailable | 3 / 0 |
| 2026-09-30 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-01 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-02 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-03 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-04 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-05 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-06 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-07 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-08 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-09 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-10 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-11 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-12 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-13 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-14 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-15 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-16 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-17 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-18 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-19 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-20 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-21 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-22 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-23 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-24 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-25 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-26 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-27 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-28 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-29 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-30 | $-0.29 | Unavailable | 3 / 0 |
| 2026-10-31 | $-0.29 | Unavailable | 3 / 0 |
| 2026-11-01 | $-0.29 | Unavailable | 3 / 0 |
| 2026-11-02 | $-0.29 | Unavailable | 3 / 0 |
| 2026-11-03 | $-0.29 | Unavailable | 3 / 0 |
| 2026-11-04 | $-0.29 | Unavailable | 3 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.